Alivus Life Sciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Non-GPL business grew 27.6% QoQ and 26.5% YoY, driven by strong momentum across all geographies and new product launches
  • GPL business witnessed de-growth of 52.6% YoY due to inventory rationalization, expected to recover in H2FY27
  • Cumulative DMF/CEP filings reached 617 across major markets as of 30th June 2026
  • Added 5 synthetic small molecules to development grid during Q1FY27

Segment-wise Performance

  • Non-GPL business contributed 89% of total revenue in Q1FY27
  • GPL business contributed 11% of total revenue in Q1FY27
  • Regulated markets contributed 83% of Q1FY27 revenues
  • Chronic therapies contribution increased during the quarter due to lower sales in GPL acute segment

Financial Highlights

Revenue: ₹6,404 million (-7.1% QoQ, +6.4% YoY)

EBITDA: ₹2,341 million (-1.3% QoQ, +29.1% YoY)

PAT: ₹1,601 million (-1.6% QoQ, +31.8% YoY)

EPS: Not Specified

Margins: Gross Margin 60.2% (+510 bps YoY), EBITDA Margin 36.6% (+220 bps QoQ, +650 bps YoY), PAT Margin 25.0% (+140 bps QoQ, +480 bps YoY)

YoY/QoQ comparison: Revenue declined QoQ but grew YoY; PAT declined slightly QoQ but grew significantly YoY

Drivers of financial performance: Favorable product mix, new launches, better operational efficiencies, strong non-GPL business growth

Key Risks: Geopolitical uncertainties, inventory rationalization in GPL business

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Regulated markets contributed 83% of revenues

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Strong free cash flow generation of ₹901 million, Cash and Cash Equivalents (including short term investments) of ₹8,802 million as of 30th June 2026

Capex & Cash Flow Health

Capital Expenditure: Ongoing capacity expansion projects

Free Cash Flow: ₹901 million

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Capacity expansion, technology upgrades, backward integration, automation, continuous manufacturing

Strategic & R&D Initiatives

Investments in Innovation: New R&D facility in Taloja (Navi Mumbai) focusing on flow chemistry, complex products, particle engineering, oncology research and green chemistry; 29 HP API products in active development grid with TAM of ~$82 billion; Iron complexes portfolio advancement

Expected impact on growth: Strengthening pipeline across key therapeutic areas

Strategic Rationale: Expanding into high-growth markets, reducing operational costs, enhancing API R&D capabilities

Industry Trends & Business Environment

Macro/Industry Trends: Geopolitical uncertainties, market growth in regulated markets

Impact on Company: Stable product mix despite geopolitical uncertainties

Management Commentary & Growth Outlook

Strategic Outlook: "We are pleased to begin the first quarter of FY27 on a positive note demonstrating the resilience of our business model, strong execution and accelerating traction in the non-GPL business" - Dr. Yasir Rawjee, Managing Director & CEO

FY Guidance: Revenue growth of 10-12% in FY27; EBITDA margins sustained in 30-32% range; GPL business expected to be flattish in FY27 despite significant decline in Q1FY27

Market Share Targets: Not Specified

Risks and Opportunities: GPL business historically skewed towards H2, expected to recover in H2FY27

Additional Information

ROICE: ~32%

FATR: 2.2 times

Manufacturing Facilities: Ankleshwar (950.2 KL capacity), Dahej (399.9 KL), Mohol (49.1 KL), Kurkumbh (24.6 KL)

Quality Approvals: USFDA, MHRA (UK), FIMEA (Finland), Romania (Europe), PMDA (Japan), COFEPRIS (Mexico), Health Canada, KFDA (South Korea), Gujarat FDCA, ANVISA (Brazil)

Therapeutic Area Portfolio: CVS (164 filings), CNS (126), Anti-Infective (56), Diabetes (43), Dermatology (41), Urology (40), Allergy (33), Others (114)